Portfolio starting to mature
The NetScientific portfolio steadily marches forward with an increasing number of companies with significant revenue on the horizon. Wanda and ProAxsis are currently the only companies with sales, but this is about to change with the first sales of Vortex’s VTX-1 occurring and Glycotest opening a CLIA lab in H217. The company reported sales of £0.5m for 2016, which we see expanding to single (c £3m) and double (£12m) digits through 2017 and 2018 as these companies’ offerings expand.NetScientific is a healthcare IP commercialization group focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease. As of Dec 31 2016, Co. had four core portfolio companies: Vortex Biosciences, Inc., which is developing a liquid biopsy technology that aims to improve cancer diagnosis, monitoring and treatment; Wanda, Inc., which has developed an artificial intelligence platform for remote patient monitoring; ProAxsis Ltd, which is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease; and Glycotest, Inc., which is a liver diagnostics company.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.